Informatie:
Fout:
ID
15404
Beschrijving
FUSION I Assesses Safety and Tolerability of Two Doses of NATRECOR (Nesiritide) Administered to Patients With Worsening Congestive (Decompensated) Heart Failure Who Are Concurrently Receiving Their Usual Cardiac Medications and Are at High Risk for Hospitalization.; ODM derived from: https://clinicaltrials.gov/show/NCT00270361
Link
https://clinicaltrials.gov/show/NCT00270361
Trefwoorden
Versies (1)
- 30-05-16 30-05-16 -
Geüploaded op
30 mei 2016
DOI
Voor een aanvraag inloggen.
Licentie
Creative Commons BY 4.0
Model Commentaren :
Hier kunt u commentaar leveren op het model. U kunt de tekstballonnen bij de itemgroepen en items gebruiken om er specifiek commentaar op te geven.
Itemgroep Commentaren voor :
Item Commentaren voor :
U moet ingelogd zijn om formulieren te downloaden. AUB inloggen of schrijf u gratis in.
Eligibility Heart Failure, Congestive NCT00270361
Eligibility Heart Failure, Congestive NCT00270361
- StudyEvent: Eligibility
Similar models
Eligibility Heart Failure, Congestive NCT00270361
- StudyEvent: Eligibility
Name
Type
Description | Question | Decode (Coded Value)
Datatype
Alias
congestive heart failure; therapeutic procedure
Item
subjects having had at least two hospital admissions (or equivalent treatment) for acutely decompensated chf within the last 12 months, with at least one of these admissions in the past 30 days, and having received treatment with intravenous vasoactive agents (such as intravenous inotropes, natrecor®, or nitroglycerin)
boolean
C0018802 (UMLS CUI [1])
C0087111 (UMLS CUI [2])
C0087111 (UMLS CUI [2])
congestive heart failure, decompensated, recent
Item
able to be enrolled and initiate treatment with study drug within 5 to 30 days of last hospital discharge (or equivalent treatment) of acutely decompensated chf
boolean
C0018802 (UMLS CUI [1,1])
C0205434 (UMLS CUI [1,2])
C0332185 (UMLS CUI [1,3])
C0205434 (UMLS CUI [1,2])
C0332185 (UMLS CUI [1,3])
nyha
Item
have a baseline nyha (new york heart association) functional classification iii or iv for at least 2 months prior to randomization
boolean
C1275491 (UMLS CUI [1])
oral medication
Item
currently receiving optimal treatment with long term oral medications (e.g., diuretics, ace inhibitors, and beta blockers, unless beta blockers or ace inhibitors are documented to be contraindicated or not tolerated)
boolean
C0175795 (UMLS CUI [1])
informed consent
Item
willing to receive infusions of natrecor®, or possibly other medications, at least as frequently as once per week for 12 weeks.
boolean
C0021430 (UMLS CUI [1])
systolic blood pressure
Item
subjects having systolic blood pressure consistently less than 90 mm hg
boolean
C0871470 (UMLS CUI [1])
organ transplantation
Item
having had organ transplantation (heart, liver, lung and kidney) in the past or anticipating organ transplantation during the study
boolean
C0029216 (UMLS CUI [1])
informed consent, inotropes
Item
not able or willing to discontinue intermittent or continuous infusions of inotropes if randomized to a natrecor® treatment group
boolean
C0021430 (UMLS CUI [1,1])
C0304509 (UMLS CUI [1,2])
C0304509 (UMLS CUI [1,2])
biventricular pacemaker
Item
having had a bi-ventricular pacemaker placed within the past 60 days or an automatic implantable cardiac defibrillator placed within the past 30 days
boolean
C1719274 (UMLS CUI [1])
C0162589 (UMLS CUI [2])
C0162589 (UMLS CUI [2])
dialysis
Item
requiring chronic dialysis or have an expectation that dialysis will be required during the course of the study.
boolean
C0011946 (UMLS CUI [1])